These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30181842)

  • 21. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
    Valke LLFG; Verhagen MJA; Mulders BTPM; Polenewen R; Blijlevens NMA; Jansen JH; Mansouritorghabeh H; Elsheikh E; Reipert BM; Turecek PL; O'Donnell JS; Rijpma SR; Schols SEM; van Heerde WL; Meijer D
    Thromb Res; 2023 Nov; 231():112-120. PubMed ID: 37844518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.
    Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V
    Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful management of total knee replacement in a high responder hemophilia patient with a history of inhibitor.
    Dolatkhah R; Bazavar MR; Poureisa M; Asvadi Kermani I; Vaez Gharamaleki J; Sanaat Z; Eivazi Ziaei J; Nikanfar A; Esfahani A; Chavoshi SH
    Iran Red Crescent Med J; 2013 Jan; 15(1):18-20. PubMed ID: 23486529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
    Oldenburg J; Shima M; Kruse-Jarres R; Santagostino E; Mahlangu J; Lehle M; Selak Bienz N; Chebon S; Asikanius E; Trask P; Mancuso ME; Jiménez-Yuste V; von Mackensen S; Levy GG
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28474. PubMed ID: 32776489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
    Négrier C; Oldenburg J; Kenet G; Meeks SL; Bordet JC; Müller J; Le Quellec S; Turecek PL; Tripkovic N; Dargaud Y
    Res Pract Thromb Haemost; 2022 May; 6(4):e12731. PubMed ID: 35765670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A: a first report.
    Mousavi SH; Mesbah-Namin SA; Rezaie N; Jazebi M; Zeinali S
    Blood Coagul Fibrinolysis; 2018 Dec; 29(8):697-700. PubMed ID: 30439768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
    Oomen I; Verhagen M; Miranda M; Allacher P; Beckers EAM; Blijlevens NMA; van der Bom JG; Coppens M; Driessens M; Eikenboom JCJ; Fijnvandraat K; Hassan S; van Heerde WL; Hooimeijer HL; Jansen JH; Kaijen P; Leebeek FWG; Meijer D; Paul H; Rijpma SR; Rosendaal FR; Smit C; van Vulpen LFD; Voorberg J; Schols SEM; Gouw SC
    Front Immunol; 2024; 15():1355813. PubMed ID: 38455035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
    Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM;
    J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Study of Clinical Profile and Treatment in Adult Hemophilia Patients with Special Reference to the Inhibitor Levels.
    Vasava R; Shastri M; Rathod VM; Laha G; Vaishnovi V; Patel NJ; Deshagoni R; Singh P; Joshi N; Raval DM
    Cureus; 2024 Feb; 16(2):e54663. PubMed ID: 38524060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
    Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
    J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
    Escobar M; Agrawal N; Chatterjee S; Bhattacharya S; Caicedo J; Bullano M; Schultz BG
    J Med Econ; 2023; 26(1):574-580. PubMed ID: 36989380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
    Shinozawa K; Yada K; Kojima T; Nogami K; Taki M; Fukutake K; Yoshioka A; Shirahata A; Shima M;
    Thromb Haemost; 2021 May; 121(5):603-615. PubMed ID: 33254277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical profile of hemophilia B patients from Karnataka.
    Kulkarni S; Hegde R; Hegde S; Kulkarni SS; Hanagvadi S; Das KK; Kolagi S; Gai PB; Bulagouda RS
    J Family Med Prim Care; 2022 Jun; 11(6):2735-2738. PubMed ID: 36119352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction.
    de Lima Montalvão SA; Tucunduva AC; de Almeida Sambo AL; De Paula EV; de Souza Medina S; Ozelo MC
    Thromb Res; 2015 Dec; 136(6):1280-4. PubMed ID: 26344704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.